Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q8NHM4

UPID:
TRY6_HUMAN

ALTERNATIVE NAMES:
Serine protease 3 pseudogene 2; Trypsinogen C

ALTERNATIVE UPACC:
Q8NHM4

BACKGROUND:
The protein known as Putative trypsin-6, with alternative names Serine protease 3 pseudogene 2 and Trypsinogen C, is implicated in the regulation of cell migration. This suggests a fundamental role in various biological processes, potentially including tissue regeneration and immune response.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Putative trypsin-6 offers a promising avenue for the development of novel therapeutic approaches. Given its regulatory role in cell migration, targeting this protein could lead to breakthroughs in treating conditions characterized by abnormal cell movement.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.